Purpose: Aminopeptidase N (APN/CD13) plays an important role in tumor neoangiogenic process and the development of metastases. Furthermore, it may serve as a potential target for cancer diagnosis and therapy. Previous studies have already shown that asparagine-glycinearginine (NGR) peptides specifically bind to APN/CD13. The aim of the study was to synthesize and investigate the APN/CD13 specificity of a novel 68
Introduction
Angiogenesis, the formation of new blood vessels from pre-existing vasculature is a fundamental physiological process (Simons 2005) ; nevertheless this process might be triggered and enhanced by many human diseases including cancer (Folkman 2002) , congestive heart failure (Higuchi et al., 2008) , atherosclerotic plaque and peripheral artery disease (Carmeliet and Jain 2000; Wu et al., 2013) . Numerous studies also suggest that tumorvasculature formation is followed by a characteristic sequence of events, mediated and controlled by growth factors, adhesion molecules, and cellular receptors (Ellis et al., 2001; Yancopoulos et al., 2000) , which can serve as a biochemical platform for targeted tumor diagnosis and therapy (Haubner et al., 1999 (Haubner et al., , 2001 Wang et al., 2011; Dijkgraaf et al., 2013) .
Related to this process, two important targets have already been revealed on the new tumor vasculatures; integrins (Ellis et al., 2001; Seong Choe et al., 2007; Haubner, 2006) and Aminopeptidase N (APN or CD13) (Pasqualini et al., 2000; Corti et al., 2008) . The latter is a zinc-dependent, trans-membrane exopeptidase that also plays an important role in metastatic tumor cell invasion through enzyme-catalyzed degradation of extracellular matrix components (Rundhaug 2005) . Furthermore, high expression of CD13 can be detected in a number of human solid tumors, including melanoma (van Hensbergen et al., 2004) , prostate, lung and ovarian cancer ).
An asparaginyl-glycinyl-arginine (NGR) sequence containing peptides have been identified via phage display as specific ligands of CD13 . Also, it was found to bear a threefold higher efficacy for the detection of neoangiogenic vessels than RGD (argininylglycinyl-aspartic acid) peptides (Buehler et al., 2006) that are widely used for the detection of α ν β 3 and α ν β 5 integrin-expression. As such, several studies have reported that the conjugation of an NGR motif with chemotherapeutic drugs might lead to improved and more specific tumor-therapy (Arap et al., 1998; Curnis et al., 2000) or the labeling of such derivative with 64 Cu or 68 Ga (Zhang et al., 2014; Shao et al., 2014a ) (PET-imaging) or with 99m
Tc Ma et al., 2014) (SPECT-imaging) can serve as useful radiotracers for the in vivo imaging of CD13-expression of tumors and neovasculature by binding to APN. Moreover, NGR based radioligands beside the diagnostic purpose might also make it feasible to monitor a tumor's response to therapy, which is important to follow the efficacy of the treatment.
Among in vivo, functional imaging techniques, Positron Emission Tomography is one of the most sophisticated methods that also makes it possible to detect tumors with high accuracy and sensitivity followed by easy quantification (Wester 2007 Ga-generators and offers a well-established complexation chemistry for the labeling of biomolecules (Velikyan 2013; Smith et al., 2013; Banerjee and Pomper 2013) . To our knowledge, only a few 68 Ga-labeled NGR conjugates were evaluated under preclinical circumstances for CD13-expression-imaging (Zhang et al., 2014; Shao et al., 2014b) . As it has been shown that the cyclic form of NGR has approximately ten-fold greater targeting efficacy than linear configurations of the same peptide sequence for targeting different tumors (Colombo et al., 2002) , a cyclic NGR motif containing radiotracer might lead to high diagnostic efficiency. On the other hand, in order to create a 68 Ga-labeled c(NGR) conjugate a chelator other than DOTA with the ability to efficiently chelate trivalent galliumion at room temperature must be chosen, as thermal stability of a DOTA-c(NGR) conjugate might be insufficient due to decomposition of the cycle or the elevated temperature can enhance the conversion of asparagine residue into isoaspartate and aspartate resulting in isoDGR and DGR sequence .
In present study, we intended to combine the advantages of the high affinity of cyclic NGR peptide with simple, room-temperature 68 Ga-labeling of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) to create a highly specific radiotracer for the detection of CD13-positive tumors. For homing devices, c[KNGRE]-NH 2 (cyclic(lysine-asparagine-glycinearginine-glutamic acid amide)) cyclic peptide (Negussie et al., 2010) was selected in this study because of its significantly higher stability against deamidation compared to cyclic NGR peptides with disulfide bridge. (The comparison of stability of cyclic NGR peptides will be published in a following study). In addition, PET-imaging properties of the new tracer were compared to commercially available, 68 Ga-labeled NODAGA-RGD dimer acetate on the very same syngenic, rat tumor models Rozsa et al., 2009) Ga-NOTA-c(NGR).
Materials and Methods

Chemicals
All commercially available chemicals were of analytical grade and used without further purification. All amino acid derivatives for peptide synthesis were purchased from Reanal (Budapest, Hungary) and IRIS Biotech GmbH (Marktredwitz, Germany), while solvents for synthesis and purification were obtained from Molar Chemicals Kft (Budapest, Hungary).
For the radiolabeling studies, Ultrapur ® water, HCl and NaOH were obtained from Merck. All other chemicals were the product of Sigma-Aldrich Co. (St. Louis, MO, USA), if not specifically stated otherwise.
Synthesis of c[KNGRE]-NH 2 cyclic peptide with amide bond
Linear semi-protected H-Lys(ClZ)-Asn-Gly-Arg-Glu-NH 2 was prepared manually by
Bu strategy on Rink-Amide MBHA resin (0.52 mmol/g capacity). Standard Fmocamino acid derivatives were used for the synthesis except Boc-Lys(ClZ)-OH that was attached to the N-terminus of the peptide. The semi-protected peptide was cleaved from the resin using a mixture of 95 % TFA, 2.5 % TIS and 2.5 % water (v/v/v) for 3 h at room temperature and then precipitated and washed three times with ice-cold diethyl ether. The product was dissolved in 100 % acetic acid and freeze dried. The crude peptide was purified by semi-preparative RP-HPLC followed by counter ion exchange of TFA to chloride using pyridinium hydrochloride prior cyclization. The semi-protected linear peptide was cyclized in DMF at 0.2 mg/mL peptide concentration in the presence of BOP/HOBt/DIEA (6:6:12 equiv to the peptide) reagents at RT for 24 h. The solvent was evaporated and the remaining oily product was dissolved in eluent A and purified by RP-HPLC. After lyophilization the purified product was dried further in dessiccator over P 2 O 5 and then the ClZ group from the side chain of Lys residue was removed with liquid HF (HF -p-cresol = 10 mL : 1 g). The crude product was purified by semi-preparative RP-HPLC and analyzed by analytical HPLC, as described below. Identification was performed with ESI-MS (Esquire 3000+ ion trap mass spectrometer Bruker Daltonics, Bremen, Germany). Extraction Disc Cartridge. (The cartridge was previously activated applying a 500 µL EtOH and then a 10 mL water wash.) After binding reacted materials from the mixture, the surface was washed with 15 mL water and then retained activity was eluted with 500 µL EtOH/0.9 % NaCl (1:1) -solution. From the eluate, EtOH-content was evaporated in approx. 5 min under 60 mL/min He flow and at 95°C. Final volume was completed to 250 µL with water in order to gain an isotonic final product for further use. Radiochemical purity (%) of the final product was determined by applying an HPLC method described below.
Conjugation reaction of c[KNGRE]-NH
Radiolabeling of NOTA-c(NGR) with Ga-68
This labeling protocol is based on the procedure desribed by Wängler et al. (2011 Ga-generator was eluted with 1 M HCl (aq). A fraction of 1 mL volume containing the highest activity (≈160 MBq) was collected, buffered with sodium-acetate (1M; 1 mL, aq.) and the pH of the stock solution was adjusted to ~4.5 by the addition of sodiumhydroxide (10 %, 0.2 mL, aq.). Then, 15 µL of a 1 mM NOTA-c(NGR) aq. solution was added and the mixture was let incubate for 5 min at room temperature. Afterwards, the reaction mixture was transferred dropwise onto the surface of a pre-activated Empore ® C18 SD 7mm/3mL Extraction Disc Cartridge. After binding reacted materials from the mixture, the surface was washed with 5 mL water and then retained activity was eluted with 0.35 mL EtOH. From the eluate, solvent was evaporated to dryness in approx. 5 min under 60 mL/min
He flow. The labeled peptide was re-dissolved in 250 µL with isotonic saline solution for further use. Radiochemical purity (%) of the final product was determined by applying an HPLC method described below.
Reversed Phase High Performance Liquid Chromatography (RP-HPLC) methods
For the synthesis of c[KNGRE]-NH 2 peptide, the crude products and the conjugates were purified on a KNAUER 2501 HPLC system (KNAUER, Bad Homburg, Germany) using a semi-preparative Phenomenex Luna C18 column (250 mm x 10 mm) with 10 μm silica (100 For the quality control of the radiolabeled peptides, in comparison with the NOTA-c(NGR) conjugate purification, a similar configuration and the same eluents were used on the previously mentioned KNAUER HPLC system with an analytical Supelco Discovery® Bio
Wide Pore C18 column (250 mm x 4.6 mm) with 10 μm silica and 1.2 mL/min flow rate, with a gradient profile: 0 min 0% B, 3 min 0 % B; 14 min 40 % B. Signals were simultaneously detected by radiodetector and UV detector (254 nm).
Determination of partition coefficient of 68
Ga-NOTA-c(NGR)
The partition coefficient of 
Determination of in vitro stability of 68
Ga-NOTA-c(NGR)
The stability of 68 Ga-NOTA-c(NGR) was tested in PBS at 95ºC and in rat serum at 37ºC.
Approximately 8 MBq of 68
Ga-NOTA-c(NGR) was pipetted into 0.5 mL PBS or into rat serum and was incubated at the respective temperature. For 95ºC study, an aliquot of the solution was directly transferred to reversed-phase HPLC testing (as described above) for the determination of radiochemical purity at various time points (0, 5, 30 and 60 min). For rat serum stability study, at various time points (0, 30, 60, 90 and 120 min) a 50 µL aliquot of the stock solution was mixed with 50 µL cold abs. EtOH. Precipitated fraction was separated by centrifugation at 20,000 rpm for 5 min. The supernatant was collected, further diluted with water and transferred to reversed-phase HPLC testing (as method prescribed above) for the determination of radiochemical purity.
Animals
Animals (Fischer-344 rats) were housed under conventional conditions in air conditioned rooms at a temperature of 26±2°C, with 50±10% humidity and artificial lighting with a circadian cycle of 12 h. The semi-synthetic diet (Charles River Hungary Ltd., Gödöllő, Hungary) and drinking water were available ad libitum to all the animals. The animals received human care complying with the criteria outlined in the "Guidelines for the welfare and use of animals in cancer research" (Workman et al., 1988) 
Experimental tumor
Chemically induced rat mesenchymal mesoblastic nephroma (NeDe) tumor was used in our experiments Rozsa et al., 2009 ). The experimental renal tumor was isolated from Fischer 344 rats which had been treated at newborn age by the i.p. injection of 125 µg/animal N-nitrosodimethylamine in saline. Tumors were removed 5-7 months after chemical tumorogenesis, minced into smaller pieces, then the tumor slices were frozen (Dezso et al., 1991) and the NeDe cell line was established (Rozsa et al., 2009 ).
Tumor models
Adult male Fischer-344 rats ( Animals were anaesthetized by 3% isoflurane with a dedicated small animal anesthesia device and the retroperitoneum was opened by abdominal section, the left kidney was exposed and the Gelaspon ® disc containing tumor cells was placed under the renal capsule. Stitches were put in the wound and the tumors were allowed to grow until 1.4-1.6 cm 3 and in vivo experiments were carried out. min after tracer injection animals were anaesthetized by 3% isoflurane with a dedicated small animal anesthesia device and whole body PET scans (10-min static PET scans at each bed position) were acquired using the MiniPET-II small animal PET scanner (Lajtos et al., 2013) . 
Small animal PET imaging using radiopharmaceuticals
The
PET data analysis
Radiotracer uptake was expressed in terms of standardized uptake values (SUVs) and tumor to muscle (T/M) ratios. Ellipsoidal 3-dimensional volumes of interest (VOI) were manually drawn around the edge of the tumor activity by visual inspection using BrainCad software (http:/www.minipetct.hu). The standardized uptake value (SUV) was calculated as follows:
, assuming a density of 1 g/mL. The T/M ratios were computed as the ratio between the activity in the tumor VOI and in the background (muscle) VOI.
Ex vivo organ distribution studies
One day after PET scans, control and tumor-bearing experimental animals were anaesthetized and 7.4±0. Packard Cobra, Waltham, MA, USA). The weight and the radioactivity of the samples were used to determine the differential absorption ratio (DAR). DAR value was calculated as:
(accumulated radioactivity/g tissue) DAR = ----------------(total injected radioactivity/body weight) biodistribution studies were performed as described above.
Blocking experiments
Western blot analysis
Cells were harvested in lysis buffer (20 mM Tris-HCl, pH 7.4, 5 mM EGTA, 1 mM 4-(2-aminoethyl)benzensulfonyl fluoride, protease inhibitor cocktail diluted 1:100, while frozen tissue samples were pulverized under liquid nitrogen with a mortar and pestle and the resulting powder was subsequently dissolved in the lysis buffer mentioned above. After sonication the protein content of the resulting samples was determined by a modified BCA protein assay (Pierce Protein Biology Products, Thermo Fisher Scientific Inc., Rockford, IL, USA Rochester, NY, USA). To assess equal loading, when indicated, membranes were re-probed with anti-β-actin antibodies (1:1000 dilution in 5% milk containing PBS) and visualized as described above.
Statistical analysis
Data are presented as mean ± SD of at least three independent experiments. The significance was calculated by Student's t test (two-tailed). The significance level was set at p ≤ 0.05 unless otherwise indicated. 
Results
Chemical and radiochemical synthesis
Partition coefficient and in vitro stability of 68
Ga-NOTA-c(NGR)
The partition coefficient (logP) of 68 Ga-NOTA-c(NGR) was determined to be -2.77 ± 0.12, suggesting that the radiotracer is highly hydrophilic. Also, stability of the labeled peptide was measured in rat serum at 37ºC and at increased temperature (PBS; pH = 7.4; T = 95ºC) by means of analytical radio-HPLC. After 2 hours of incubation in rat serum, more than 95 % of the original labeled peptide was found to be intact; also at increased temperature first signs of degradation was observed only at 1 hour, when still 98%< radiochemical purity was found.
These latter results suggest a highly stable molecule under the applied conditions in the following experiments.
In vivo and ex vivo biodistribution studies on healthy animals
In vivo and ex vivo biodistribution studies were performed using healthy Fischer-344 rats as Ex vivo blocking studies were performed on healthy animals as described in Ga-NOTA-c(NGR) uptake of the organs or tissues was lower after the injection of 200 µg unlabeled NOTA-c(NGR). The radiotracer uptake in the selected organs was approximately two-fold higher without the blockade (Table   1) .
Table 1
Tracer uptake (DAR) in selected organs/tissues 90 min after tracer injection
In vivo and ex vivo biodistribution studies on subcutan tumor model
The tumor targeting efficacy of Significance level: p≤0.01 (*).
These miniPET results correlated with the ex vivo bidistribution data where the s.c. NeDe tumor-bearing rats were sacrificed 90 min after the tracer injection, dissected, and the accumulated activity of the tumors and muscle (as background) was counted with a gamma counter and DAR values were calculated. The results are summarized in Table. 2.
Table 2
Tracer uptake (DAR) in s.c. NeDe tumors 90 min after tracer injection The ex vivo biodistribution data of the subrenal NeDe tumor bearing rats are summarized in Table 3 . Rats were sacrificed 90 min after the tracer injection, dissected and the accumulated activity of the tumors and muscle (as background) was counted with a gamma counter and DAR values were calculated.
Table 3
Tracer uptake (DAR) in SRCA NeDe tumors 90 min after tracer injection
In vivo and ex vivo biodistribution studies on metastases
Two weeks after NeDe cell implantation under the left renal capsule metastatic lymph nodes were found in the tumor bearing rats. By autopsy we found that the mesenteric lymph nodes in the abdomen and the parathymic lymph nodes in the thorax showed tumorous infiltration (Fig. 7) . The CD13 expression of the metastatic lymph nodes was confirmed by western blot analysis (Fig. 8) . The accumulation of Ga-labeled radiotracer, the accumulation in the lymph nodes was blocked efficiently confirming the CD13 binding specificity (Fig. 7E ). 
Discussion
Nowadays, the PET and SPECT imaging of tumor neoangiogenesis with isotope labeled tracers targeting Aminopeptidase N (APN/CD13) and integrin receptors is an intensively investigated field in oncology (Faintuch et al., 2014; Ma et al., 2013 Ma et al., , 2014 . In this paper, we focused on the PET imaging of APN/CD13 receptor expression in experimental rat tumor models using a new 68 Ga labeled radiotracer NOTA-c(NGR).
APN/CD13 is a membrane-associated exopeptidase, involved in the angiogenesis and metastatic process by degradation of extracellular matrix (Su et al., 2012) , furthermore, one of the promising tumor associated targets for imaging of cancer and tumor vasculature. In addition, APN/CD13 is a promising target in anti-angiogenic therapy .
The asparaginyl-glycinyl-arginine (NGR) peptide has been identified as the specific ligand of
Aminopeptidase N and has a higher efficacy for the detection of neoangiogenic vessels than the integrin receptor specific RGD peptides (Arap et al., 1998 (Zhang et al., 2014; Shao et al., 2014b; Ma et al., 2013 Ma et al., , 2014 .
This current study aimed to investigate newly synthesized Ga with a RCP of 95%< and a specific activity of 5.13 -5.92 GBq/µmol with a protocol based on the labeling procedure described by Wängler et al. Ga-NODAGA-[c(RGD) ] 2 was performed for control experiments with a labeling procedure based on the description of Notni et al. (2011) .
The in vitro experiments demonstrated that newly synthesized 68 Ga-NOTA-c(NGR) is highly hydrophilic (logP = -2.77 ± 0.12) and was also found to be stable both in PBS at increased temperature (T = 95ºC) for 1 hour and in rat serum at 37°C for 2 h; these results demonstrate that 68 Ga-NOTA-c(NGR) is an appropriate candidate for further experiments.
Ex vivo and in vivo biodistribution studies on control animals revealed that 68 Ga-NOTAc(NGR) was mainly excreted from the kidney, due to its hydrophilic properties that has been proved by the partition coefficient. On the other hand, the uptake of the tracer in other organs was very low, especially in the abdomen (Fig. 2) Ga-DOTA-NGR (Zhang et al., 2014) and 68 Ga-NOTA-NGR ) molecules were investigated. Furthermore, the low activity of other organs also allowed for high quality images with low background and high tumor-to-muscle ratios to be obtained.
In our study, we investigated the tumor specific accumulation of 
Conclusion
In this study, we have synthesized 68 Ga-NOTA-c(NGR) with high radiochemical purity and stability. Due to its high selectivity and strong binding affinity to APN/CD13, favorable biodistribution and pharmacokinetics, 68 Ga-NOTA-c(NGR) might be a potential molecular probe for the noninvasive detection of CD13/APN-positive tumors, metastases and neovasculature.
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